Top in allergy/asthma: Price cap on inhaler products; NIH grant for Cincinnati Children's
Click Here to Manage Email Alerts
The Allergy & Asthma Network praised three major pharmaceutical companies, AstraZeneca, Boehringer Ingelheim and GSK, that announced they will enact a $35 price cap on their inhaler products.
According to the CDC, patients with above average copays on their asthma medication tend to skip prescription refills.
“It is very important that people with asthma use their asthma medications as prescribed,” Allergy & Asthma Network (AAN) CEO Lynda Mitchell, MA, CAE, told Healio. “Those who go without taking their medication, whether it’s a quick-relief inhaler or daily controller inhaler, may see their asthma worsen — and for some symptoms may become life-threatening.”
The AAN argues that price caps on other drugs, such as epinephrine for anaphylaxis, should be implemented to promote accessibility. It was the top story in allergy/asthma last week.
In another top story, the Cincinnati Children’s Hospital Medical Center received a 7-year grant from the NIH to join the Consortium of Food Allergy Research as a clinical research center.
Read these and more top stories in allergy and asthma below:
Allergy & Asthma Network says $35 inhaler price cap will improve health, wellness
After three major pharmaceutical companies said they will enact a monthly $35 price cap on their inhaler products, the Allergy & Asthma Network applauded this move to make treatment more affordable for patients. Read more.
Cincinnati Children’s receives NIH grant to become CoFAR clinical research center
Cincinnati Children’s Hospital Medical Center has been selected as a recipient of an NIH grant to join the Consortium of Food Allergy Research as a clinical research center. Read more.
Delaware lawmakers pass first early allergen introduction bill
Introduced by Delaware Rep. Kimberly Williams (D-19) in January, HB 274 would provide caregivers in the state with at least one peanut and one egg food allergen supplement to reduce the risk of developing these allergies. Read more.
PICU admission for anaphylaxis often involves drug reactions, breathing difficulties
When children have anaphylaxis with breathing difficulties, drug reactions and epinephrine doses, pediatric ICU admission is likely, according to a poster presentation at the American Academy of Allergy, Asthma & Immunology Annual Meeting. Read more.
Top news of March: Oral allergy syndrome, lockdown babies, food allergy treatment
Healio has compiled March’s most-read news in asthma and allergy. Read more.